Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Grohar

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Pediatric Blood & Cancer|June 17, 2021
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task ForceSarah B Whittle, Katharine Offer, Ryan D Roberts, et al.
Journal of Medicinal Chemistry|June 1, 2001
Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activityM C Schroeder, J M Hamby, C J Connolly, et al.
NPJ Precision Oncology|September 17, 2022
An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcomaDavid S Shulman, Sarah B Whittle, Didier Surdez, et al.
NPJ Precision Oncology|May 5, 2026
An international framework for clinical translation of molecular classifiers in osteosarcomaAmanda E Marinoff, Michaela Nathrath, David S Shulman, et al.
Molecular Cancer Therapeutics|September 5, 2025
Advancing preclinical biology for Ewing Sarcoma: an international effortFilemon S Dela Cruz, Elizabeth A Stewart, Didier Surdez, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 27, 2024
Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: A Children's Oncology Group Bone Tumor Committee Consensus StatementMatthew S Dietz, Alyaa Al-Ibraheemi, Jessica L Davis, et al.
Nature Medicine|April 16, 2026
Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trialPatrick J Grohar, Rachel Heise, Mary Frances Wedekind, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Pediatric Blood & Cancer|June 17, 2021
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task ForceSarah B Whittle, Katharine Offer, Ryan D Roberts, et al.
Journal of Medicinal Chemistry|June 1, 2001
Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activityM C Schroeder, J M Hamby, C J Connolly, et al.
NPJ Precision Oncology|September 17, 2022
An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcomaDavid S Shulman, Sarah B Whittle, Didier Surdez, et al.
NPJ Precision Oncology|May 5, 2026
An international framework for clinical translation of molecular classifiers in osteosarcomaAmanda E Marinoff, Michaela Nathrath, David S Shulman, et al.
Molecular Cancer Therapeutics|September 5, 2025
Advancing preclinical biology for Ewing Sarcoma: an international effortFilemon S Dela Cruz, Elizabeth A Stewart, Didier Surdez, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 27, 2024
Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: A Children's Oncology Group Bone Tumor Committee Consensus StatementMatthew S Dietz, Alyaa Al-Ibraheemi, Jessica L Davis, et al.
Nature Medicine|April 16, 2026
Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trialPatrick J Grohar, Rachel Heise, Mary Frances Wedekind, et al.
Pageof 5